{"id":55431,"date":"2024-02-06T23:57:47","date_gmt":"2024-02-06T23:57:47","guid":{"rendered":"https:\/\/medsname.com\/sulpitac\/"},"modified":"2026-04-30T10:24:48","modified_gmt":"2026-04-30T10:24:48","slug":"sulpitac","status":"publish","type":"product","link":"https:\/\/medsbase.com\/el\/sulpitac\/","title":{"rendered":"Sulpitac"},"content":{"rendered":"

<\/p>\n

\n

\u26a1 \u0393\u03c1\u03ae\u03b3\u03bf\u03c1\u03b7 \u0391\u03c0\u03ac\u03bd\u03c4\u03b7\u03c3\u03b7<\/h3>\n

Sulpitac (Amisulpride 50 \/ 100 \/ 200 \/ 400 mg) is a benzamide atypical antipsychotic for schizophrenia. Dose-dependent dual mechanism \u2014 low doses (50\u2013300 mg) treat negative symptoms; higher doses (400\u20131200 mg) treat positive symptoms. Largely renally cleared. Available across Europe and Asia; not FDA-approved.<\/p>\n<\/div>\n

\n\u0391\u03c5\u03c4\u03cc \u03c0\u03bf\u03c5 \u03bb\u03b1\u03bc\u03b2\u03ac\u03bd\u03b5\u03c4\u03b5 \u03bc\u03b5 \u03c4\u03b7\u03bd MedsBase:<\/strong> \u03a0\u03b9\u03c3\u03c4\u03bf\u03c0\u03bf\u03b9\u03b7\u03bc\u03ad\u03bd\u03bf\u03c2 \u03ba\u03b1\u03c4\u03b1\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03c4\u03ae\u03c2 WHO-GMP \u00b7 \u0394\u03b9\u03b1\u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ae \u03c3\u03c5\u03c3\u03ba\u03b5\u03c5\u03b1\u03c3\u03af\u03b1 \u00b7 \u03a0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u00b7 1,400+ \u03b5\u03c0\u03b1\u03bb\u03b7\u03b8\u03b5\u03c5\u03bc\u03ad\u03bd\u03b5\u03c2 \u03ba\u03c1\u03b9\u03c4\u03b9\u03ba\u03ad\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>\n<\/div>\n

\ud83d\udce6 \u039a\u03ac\u03b8\u03b5 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03bb\u03af\u03b1 \u03ba\u03b1\u03bb\u03cd\u03c0\u03c4\u03b5\u03c4\u03b1\u03b9 \u03b1\u03c0\u03cc \u03c4\u03b7\u03bd \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/strong><\/a> \u2014 \u03b5\u03ac\u03bd \u03c4\u03bf \u03b4\u03ad\u03bc\u03b1 \u03c3\u03b1\u03c2 \u03b4\u03b5\u03bd \u03c6\u03c4\u03ac\u03c3\u03b5\u03b9 \u03b5\u03bd\u03c4\u03cc\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd, \u03c4\u03bf \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03ad\u03bb\u03bb\u03bf\u03c5\u03bc\u03b5.<\/p>\n

\u0393\u03b9\u03b1\u03c4\u03af \u03bd\u03b1 \u03c0\u03b1\u03c1\u03b1\u03b3\u03b3\u03b5\u03af\u03bb\u03b5\u03c4\u03b5 \u03b1\u03c0\u03cc \u03c4\u03b7 MedsBase<\/h3>\n

Sulpitac at MedsBase is supplied directly from a WHO-GMP certified manufacturer in plain, discreet packaging. Every order is covered by our \u03a0\u03bf\u03bb\u03b9\u03c4\u03b9\u03ba\u03ae \u0395\u03b3\u03b3\u03cd\u03b7\u03c3\u03b7\u03c2 \u0395\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae\u03c2<\/a> \u2014 \u03c0\u03b1\u03c1\u03ac\u03b8\u03c5\u03c1\u03bf \u03ac\u03c6\u03b9\u03be\u03b7\u03c2 20 \u03b5\u03c1\u03b3\u03ac\u03c3\u03b9\u03bc\u03c9\u03bd \u03b7\u03bc\u03b5\u03c1\u03ce\u03bd \u03ae \u03b5\u03c0\u03b1\u03bd\u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c7\u03c9\u03c1\u03af\u03c2 \u03c7\u03c1\u03ad\u03c9\u03c3\u03b7 \u2014 \u03ba\u03b1\u03b9 \u03b4\u03b9\u03ba\u03b1\u03b9\u03bf\u03cd\u03c4\u03b1\u03b9 \u03c3\u03c5\u03bc\u03bc\u03b5\u03c4\u03bf\u03c7\u03ae \u03c3\u03c4\u03bf \u03c0\u03c1\u03cc\u03b3\u03c1\u03b1\u03bc\u03bc\u03b1 \u03b1\u03c6\u03bf\u03c3\u03af\u03c9\u03c3\u03b7\u03c2 \u03c0\u03b5\u03bb\u03b1\u03c4\u03ce\u03bd<\/a>. \u0394\u03b9\u03b1\u03c4\u03af\u03b8\u03b5\u03c4\u03b1\u03b9 \u03c0\u03b1\u03b3\u03ba\u03cc\u03c3\u03bc\u03b9\u03b1 \u03b1\u03c0\u03bf\u03c3\u03c4\u03bf\u03bb\u03ae \u03c3\u03c4\u03b9\u03c2 \u03c0\u03b5\u03c1\u03b9\u03c3\u03c3\u03cc\u03c4\u03b5\u03c1\u03b5\u03c2 \u03c0\u03c1\u03bf\u03bf\u03c1\u03b9\u03c3\u03bc\u03bf\u03cd\u03c2.<\/p>\n

What Sulpitac is and how it works<\/h2>\n

Sulpitac is an amisulpride tablet supplied by Sun Pharma. Available strengths: 50 \/ 100 \/ 200 \/ 400 mg<\/strong>. Amisulpride is a benzamide atypical with selective D2\/D3 antagonism \u2014 no significant action at 5-HT2A, H1, M1, or \u03b1-adrenergic receptors. The unique feature is dose-dependent action on dopamine: at low doses (50\u2013300 mg) it preferentially blocks pre-synaptic D2 autoreceptors, increasing dopamine release in the prefrontal cortex (treats negative symptoms); at higher doses (400\u20131200 mg) it blocks postsynaptic D2 receptors (treats positive symptoms).<\/p>\n

Approved across Europe and Asia for schizophrenia; not FDA-approved (oral). The intravenous formulation is FDA-approved for postoperative nausea\/vomiting under a different brand name (Barhemsys) but with no oral availability in the US.<\/p>\n

\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2 \u03ba\u03b1\u03b9 \u03b4\u03bf\u03c3\u03bf\u03bb\u03bf\u03b3\u03af\u03b1<\/h2>\n\n\n\n\n\n\n\n\n\n
\u0395\u03bd\u03b4\u03b5\u03af\u03be\u03b5\u03b9\u03c2<\/th>\n\u0395\u03ba\u03ba\u03af\u03bd\u03b7\u03c3\u03b7<\/th>\n\u03a3\u03c4\u03cc\u03c7\u03bf\u03c2<\/th>\n\u039c\u03ad\u03b3\u03b9\u03c3\u03c4\u03bf<\/th>\n<\/tr>\n<\/thead>\n
Predominantly negative symptoms<\/td>\n50 mg OD<\/td>\n50\u2013300 mg\/day<\/td>\n300 mg<\/td>\n<\/tr>\n
Predominantly positive symptoms<\/td>\n200 mg BID<\/td>\n400\u2013800 mg\/day<\/td>\n1200 mg<\/td>\n<\/tr>\n
Mixed presentation<\/td>\n200 mg BID<\/td>\n400\u2013800 mg\/day<\/td>\n1200 mg<\/td>\n<\/tr>\n
Renal impairment (CrCl 30\u201360)<\/td>\nhalve dose<\/td>\n\u2014<\/td>\n\u2014<\/td>\n<\/tr>\n
Renal impairment (CrCl 10\u201330)<\/td>\none-third normal dose<\/td>\n\u2014<\/td>\n\u2014<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\u03a3\u03b7\u03bc\u03b1\u03bd\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b1\u03c3\u03c6\u03b1\u03bb\u03b9\u03c3\u03c4\u03b9\u03ba\u03ad\u03c2 \u03b5\u03ba\u03c4\u03b9\u03bc\u03ae\u03c3\u03b5\u03b9\u03c2<\/h2>\n
\nFDA black-box \u2014 dementia-related psychosis<\/strong><\/p>\n

All atypical antipsychotics carry an FDA black-box warning for increased mortality (mostly cardiovascular and infectious) when used to treat behavioural disturbance in older adults with dementia. Atypicals are not approved for dementia-related psychosis or agitation<\/strong>. Use in this population is off-label, last-resort, time-limited, and requires explicit risk-benefit conversation.<\/p>\n<\/div>\n

\n\u0395\u03c0\u03ad\u03ba\u03c4\u03b1\u03c3\u03b7 QT<\/strong><\/p>\n

Amisulpride produces dose-dependent QT prolongation \u2014 meaningful at higher doses. Pre-treatment ECG advised. Avoid in known long QT, hypokalaemia\/hypomagnesaemia, recent MI, uncompensated heart failure, and concurrent QT-prolonging therapy.<\/p>\n<\/div>\n

\nHyperprolactinaemia<\/strong><\/p>\n

Amisulpride raises prolactin substantially \u2014 comparable to risperidone. Same downstream effects: amenorrhoea, galactorrhoea, sexual dysfunction, accelerated osteoporosis. Switch to aripiprazole if symptomatic.<\/p>\n<\/div>\n

\nEPS \u2014 dose-dependent<\/strong><\/p>\n

EPS rises sharply above 800 mg\/day.<\/p>\n<\/div>\n

\u03a3\u03c5\u03c7\u03bd\u03ad\u03c2 \u03c0\u03b1\u03c1\u03b5\u03bd\u03ad\u03c1\u03b3\u03b5\u03b9\u03b5\u03c2<\/h2>\n